Before GLP-1 agonists became the blockbuster obesity drugs many people know and use today, Rhythm Pharmaceuticals was researching molecules that take a similar approach but for a different target. The ...
The hypothalamus is a small but critical region at the base of the brain that controls the autonomic nervous system, regulates body temperature, signals hunger and thirst, exerts hormonal control over ...
Hypothalamic obesity (HyOb) is a type of obesity caused by damage to the brain’s hunger-regulating function. While there’s no cure, proper treatment can help improve your daily life and prevent ...
Hypothalamic obesity is a complex condition. Dietary changes won’t likely result in lasting weight loss, but there are other benefits for long-term health. The hypothalamus is a small but important ...
Rhythm Pharmaceuticals announced significant data regarding their treatments for acquired hypothalamic obesity during the Endocrine Society’s Annual Meeting. Presentations highlighted the promising ...
The last time I spoke about Rhythm Pharmaceuticals, Inc. (RYTM) it was in a Seeking Alpha article entitled "Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder." With respect to ...
Bivamelagon showed significant BMI reductions in hypothalamic obesity patients, prompting Rhythm Pharmaceuticals to seek FDA guidance for Phase 3 trials. Rhythm Pharmaceuticals, Inc. announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results